Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
- 29 April 1993
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 362 (6423), 857-860
- https://doi.org/10.1038/362857a0
Abstract
THE tumour-suppressor gene p53 is inactivated in most human malignancies1 either by missense mutations1 or by binding to oncogenic proteins2–4. In human soft tissue sarcomas, inactivation apparently results from MDM2 gene amplification4. MDM2 is an oncogene product5,6 that may function by binding to p53 and inhibiting its ability to activate transcription3. Here we show that, when expressed in Saccharomyces cerevisiae, human MDM2 inhibits human p53's ability to stimulate transcription by binding to a region that nearly coincides with the p53 acidic activation domain. The isolated p53 activation domain fused to another DNA-binding protein is also inactivated by MDM2, confirming that MDM2 can inhibit p53 function by concealing the activation domain of p53 from the cellular transcription machinery.Keywords
This publication has 26 references indexed in Scilit:
- The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth.Molecular and Cellular Biology, 1993
- p53 function and dysfunctionCell, 1992
- Amplification of a gene encoding a p53-associated protein in human sarcomasNature, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992
- Oncogenic forms of p53 inhibit p53-regulated gene expressionScience, 1992
- p53 Mutations in Human CancersScience, 1991
- The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53Cell, 1990
- Transcriptional Activation by Wild-Type but Not Transforming Mutants of the p53 Anti-OncogeneScience, 1990
- Presence of a Potent Transcription Activating Sequence in the p53 ProteinScience, 1990
- Oncogenic transformation by vrel requires an amino-terminal activation domain.Molecular and Cellular Biology, 1990